Send to

Choose Destination
Ann Clin Transl Neurol. 2018 May 26;5(7):883-887. doi: 10.1002/acn3.584. eCollection 2018 Jul.

CSF nonphosphorylated Tau as a biomarker for the discrimination of AD from CJD.

Author information

Department of Psychiatry and Psychotherapy Universitätsklinikum Erlangen, and Friedrich-Alexander-Universität Erlangen-Nürnberg Erlangen Germany.
Department of Neurodegeneration Diagnostics Medical University of Białystok Białystok Poland.
Department of Biochemical Diagnostics University Hospital of Białystok Białystok Poland.
Clinical Dementia Center Department of Neurology University Medical School Göttingen Germany.
German Center for Neurodegenerative Diseases (DZNE) Göttingen Germany.
Network Center for Biomedical Research in Neurodegenerative Diseases Barcelona (CIBERNED) Institute Carlos III Ministry of Health Bellvitge Spain.


Creutzfeldt-Jakob disease and Alzheimer's disease are characterized by the presence of elevated total-Tau cerebrospinal fluid concentrations while the presence of hyperphosphorylated Tau forms in the cerebrospinal fluid is rather a hallmark of Alzheimer's disease. Here we aimed to investigate potential contribution of nonphospho-Tau epitopes (non-P-Tau) in the discrimination between both diseases. Non-P-Tau cerebrospinal fluid concentration was highly increased in Creutzfeldt-Jakob disease (n = 57, 3683 ± 3599 pg/mL) compared to Alzheimer's disease (n = 41, 148 ± 219 pg/mL) and neurological controls (n = 56, 62 ± 40 pg/mL), and significantly improved the proportion of correctly classified patients (99%) compared to that achieved by total-Tau (90%), P-Tau (62%) and 14-3-3 (91%).

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center